BioStem Technologies OTCMKTS: BSEM said its first quarter of 2026 marked a major shift in its business model following a late-January acquisition that moved the company's focus from physician offices toward the hospital market.
BioStem Technologies, Inc. (BSEM) Q1 2026 Earnings Call Transcript
BioStem Technologies, Inc. (BSEM) came out with a quarterly loss of $0.52 per share versus the Zacks Consensus Estimate of a loss of $0.28. This compares to earnings of $0.17 per share a year ago.
| Biotechnology Industry | Healthcare Sector | Jason V. Matuszewski CEO | OTC PINK Exchange | 090684200 CUSIP |
| US Country | 2 Employees | - Last Dividend | 27 Jan 2015 Last Split | - IPO Date |
BioStem Technologies, Inc. is a pioneering life sciences corporation with a core focus on the discovery, development, and production of pharmaceutical and regenerative medicine products and services. Established in 2006, the company has positioned itself at the forefront of biologic stem cell-based alternatives aimed at treating a wide array of ailments, ranging from joint pain and neurodegenerative disorders to tendon, ligament injuries, and autoimmune diseases. Apart from its therapeutic innovations, BioStem Technologies extends its expertise to the repackaging and distribution of active pharmaceutical ingredients along with other essential supplies for pharmaceutical compounding. With its headquarters nestled in Pompano Beach, Florida, the company effectively harnesses e-commerce platforms to market and sell its diverse product lineup, both domestically and internationally. Progressing towards its mission, BioStem Technologies continues to forge new paths in the life sciences sector, striving to improve patient outcomes through its cutting-edge products and services.
At the heart of BioStem Technologies' product offerings are its biologic stem cell based alternatives designed to treat various ailments. These innovative treatments are developed as part of the company's commitment to regenerative medicine, targeting conditions such as joint pain, tendon and ligament injuries, as well as neurodegenerative and autoimmune diseases. Through extensive research and development, these products aim to offer effective solutions by harnessing the natural healing power of stem cells.
BioStem Technologies also specializes in the repackaging and distribution of active pharmaceutical ingredients (APIs) and other necessary supplies for pharmaceutical compounding. This service caters to the broader needs of the pharmaceutical sector by ensuring the availability of high-quality ingredients and supplies essential for the creation of compounded medications, thereby supporting bespoke treatment options for patients.
The company has expanded its product range to include nutraceutical products marketed under the Dr. Dave's Best and Nesvik Organics brands. These offerings are part of BioStem Technologies' venture into the health and wellness segment, providing consumers with dietary supplements and organic products. Manufactured with an emphasis on quality and efficacy, these nutraceuticals aim to support overall health and complement the therapeutic benefits of the company's regenerative medicine products.
In addition to branded products, BioStem Technologies develops and markets a range of non-proprietary products. These offerings serve to broaden the company's market reach, catering to diverse consumer needs in the realm of pharmaceuticals and regenerative medicine. The non-proprietary product lineup is designed with the same commitment to quality and innovation that characterizes all of BioStem Technologies' solutions, ensuring a wide array of options for healthcare providers and patients alike.